TUCSON, Ariz., June 22, 2022 — Critical Path Institute (C-Path) is pleased to announce it has received the DIA 2022 Americas Inspire Award for Outstanding Contribution to Health. This prestigious honor is conferred upon an individual, group or organization that has made significant and innovative contributions to advancing global health.
“The work that Critical Path Institute has done through its programs has led to the development of tools and approaches to solve some of the most critical challenges in the product development pathway, including the need for aggregated data, and a platform for communication and collaboration,” wrote DIA representatives Anna McDermott-Vitak, Senior Vice President and Managing Director, Americas; and Stephanie Crawford, Ph.D., Chair, Americas Regional Advisory Council.
As also articulated by DIA, “One C-Path program, the eCOA Consortium, for example, has advanced the science of trial endpoints, particularly through a focus on patient reported outcomes through its ‘[eCOA:] Getting Better Together Initiative.’ Further, the eCOA Consortium has been a trusted and invaluable partner in the development of the DIA Digital Technology in Clinical Trials Conference that was founded in 2020.” Scottie Kern, Executive Director of the eCOA Consortium, accepted the award on behalf of C-Path at the Awards Celebration hosted by DIA’s Board of Directors in Chicago, Illinois on June 20, 2022.
“C-Path is honored to receive this prestigious award, affirming we are accomplishing our mission to accelerate the path to a healthier world,” said Kristen Swingle, M.S., C-Path Interim President and COO. “The eCOA Consortium team and everyone at C-Path would like to thank the DIA for this recognition.”
About Critical Path Institute
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and hundreds of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona, C-Path in Europe is headquartered in Amsterdam, Netherlands and C-Path Ltd. operates from Dublin, Ireland with additional staff in multiple other locations. For more information, visit c-path.org.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 54.2% funded by the FDA/HHS, totaling $13,239,950, and 45.8% funded by non-government source(s), totaling $11,196,634. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.
About C-Path’s Electronic Clinical Outcome Assessment (eCOA) Consortium
The eCOA Consortium provides a pre-competitive environment in which a critical mass of experts can collaborate to generate measurement equivalence data, develop specification documents and data standards, and provide guidance on methodological considerations related to eCOA applications. All of these activities are aimed at enhancing the quality, practicality and acceptability of electronic capture of clinical trial endpoint data.
For more information on C-Path’s eCOA Consortium, visit: